Skip to content

Released Nov 5, 2019, after the close

10-Q filed Nov 8, 2019, 39 days after period end · 0001162194-19-000088

Q3 2019 · 10-Q
Revenue$26.50M−8.5% vs Q3 2018−6.0% vs Q2 2019
Net Income-$12.89MN/M vs Q3 2018N/M vs Q2 2019
EPS Diluted-$0.19N/M vs Q3 2018N/M vs Q2 2019
Gross Profit$13,838,000−12.5%
Operating Income-$13,816,000N/M
Operating Cash Flowderived-$4,548,000N/M
Free Cash Flowderived-$5,894,000N/M
Margins · derived
Gross margin52.2%−2.4 pt vs Q3 2018
Operating margin-52.1%−12.0 pt vs Q3 2018
Net margin-48.6%+2.3 pt vs Q3 2018

What the release said

The release

Same quarter

MetricQ3 2019Q3 2018Q3 2017Q3 2016
Revenue$26.50M$28.96M$24.75M$22.19M
Net Income-$12.89M-$14.75M-$15.94M-$19.79M
EPS Diluted-$0.19-$0.38-$0.46-$0.68

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR